TIMP metallopeptidase inhibitor 1Genealiases: CLGI · EPA · EPO · HCI · TIMP · TIMP-1
Q-omics provides the consensus-scored TIMP1 profile across patient tissues and cancer cell-line models. TIMP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TIMP1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TIMP1 protein abundance shows 24,123 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where TIMP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMP1 survival associations across molecular data types. TIMP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMP1 RNA expression–survival associations across cancer types. High TIMP1 expression shows unfavorable associations in KIRC, LGG and LUSC, but favorable associations in MESO, THCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TIMP1 RNA expression.
This table summarizes TIMP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TIMP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMP1 shows higher tumor expression in KIRC, THCA, COAD, KIRP, HNSC and STAD. The KIRC box plot shows higher TIMP1 RNA expression in tumor versus normal tissue (log2 FC = +2.217, t-test p < 0.001).
This table shows molecular features associated with TIMP1 in patient tissues and cancer cell lines. In patient samples, TIMP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
